
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Versant Ventures
Deal Size : $94.0 million
Deal Type : Series A Financing
Firefly Bio Debuts with $94 Million Series A Financing
Details : The financing aims to support Firefly developing a platform for cancer treatment utilizing degrader antibody conjugates. It represents the integration of two technologies: ADCs and protein degraders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 15, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Versant Ventures
Deal Size : $94.0 million
Deal Type : Series A Financing
